NWMP
VKTX icon

Noble Wealth Management PBC’s Viking Therapeutics VKTX Stock Holding History

Noble Wealth Management PBC’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.93K Hold
274
– – ﹤0.01% 486
2026
Q2 		$10.7K Hold
274
– – ﹤0.01% 464
2026
Q1 		$8.92K Buy
+274
New +$8.81K ﹤0.01% 464

Other funds holding VKTX

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
BFS
Burkett Financial Services Rock Hill, South Carolina $331M AUM 14.93% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Noble Wealth Management PBC's VKTX Position: Q3 2026 in Review

Noble Wealth Management PBC held its Viking Therapeutics (VKTX) position steady in Q3 2026 at 274 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #486.

Noble Wealth Management PBC first reported a position in VKTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $10.7K in Q2 2026. 11 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Noble Wealth Management PBC held 274 shares of Viking Therapeutics worth $8.93K as of Q3 2026.
  • Noble Wealth Management PBC left its Viking Therapeutics share count unchanged in Q3 2026.
  • Viking Therapeutics made up ﹤0.01% of Noble Wealth Management PBC's portfolio in Q3 2026, its #486 holding.
  • Noble Wealth Management PBC first reported a position in Viking Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Noble Wealth Management PBC's Viking Therapeutics position peaked at $10.7K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Noble Wealth Management PBC's 13F filing for Q3 2026, filed 1 Oct 2026.